skip to content

The Abell Group

Fragment based drug discovery against cytochrome P450s from Mycobacterium tuberculosis

We are using fragment-based approaches to understand of the role of cytochrome P450 enzymes (CYPs) from Mycobacterium tuberculosis. CYPs are mon-oxygenases responsible for a range of oxidative modifications. M. tuberculosis has a relatively high number of CYPs, some of which are essential, and some of which are of unknown function.

Read more

Targeting the Coenzyme A pathway

We have a long term interest in the enzymology of Coenzyme A, both the pathway up to pantothenate (vitamin B5) (present in plants, microorganisms and fungi) and the pathway from pantothenate to Coenzyme A (present in all cells). We have a specific interest in targeting the coenzyme A pathway enzymes (CoaBC, CoaD, CoaE) from Mycobacterium tuberculosis.

Read more

Antibiotics for bacteria infections in cystic fibrosis

We are interested in using fragment based approaches to develop novel antibiotics for two multi-drug resistant bacterial infections affecting people with Cystic Fibrosis. We are interested in targeting enzymes from Mycobacterium abscessus and Pseudomonas aeruginosa.

Read more

Microdroplets reactors

We develop microfluidic microdroplet reactors for applications in biology and material sciences. Experiments are carried out in small water droplets, separated from each other by a continuous oil phase, within a microfluidic channel. We develop devices to generate and manipulate the droplets, and develop new analytical approaches to follow what is happening, on a very small scale, inside the droplets.

Read more

Professor Chris Abell FRS FMedSci

Pro-Vice-Chancellor for Research

Professor of Biological Chemistry

Todd-Hamied Fellow of Christ's College

Co-founder of Astex Pharmaceuticals

Co-founder of Sphere Fluidics

Co-founder of Aqdot


Royal Society of Chemistry 2020 Interdisciplinary Prize

Spin-out companies


Astex PharmaceuticalsSphere Fluidics LtdAqdot